SASCIA (GBG 102) – successful start of the study!
12.11.2020
First patient included.
The phase III postneoadjuvant study with the antibody-drug conjugate sacituzumab govitecan in women with early HER2-negative breast cancer and a high risk of relapse started successfully in November 2020.
We congratulate the gynecological clinic of the Caritasklinik St. Theresia, Saarbrücken for recruiting the first patient.
News
-
21.09.2023 New review on Immune Cell Infiltration published
A review from the International Immuno-Oncology Biomarker Working about tumor immunology was published in the journal of pathology.
Mehr ... -
07.09.2023 Save the date! GBG Annual Scientific Meeting 2024
Das 21. Annual Scientific Meeting 2024 wird am 29.2. bis 1.3. in Frankfurt stattfinden.
Mehr ... -
05.05.2023 GBG Research at ESMO-BC 2023
GBG Research at ESMO-Breast Cancer Conference 2023 in Berlin
Mehr ... -
28.02.2023 Annual Scientific Report 2022 published
Our Annual Scientific Report 2022 provides a concise overview of current study findings along with important lectures and research posters presented by our members from the last year.
Mehr ... -
24.01.2023 Save the date: 20th GBG Annual Meeting 2023
The 20th GBG Annual Meeting 2023 will start 2nd to 3rd of March 2023 at the Steigenberger Airport Hotel
Mehr ...